Antibiotic Tolerance and Treatment Outcomes in Cystic Fibrosis Methicillin-Resistant Staphylococcus aureus Infections

被引:6
|
作者
Lu, Kuan-Yi [1 ]
Wagner, Nikki J. [1 ]
Velez, Amanda Z. [1 ]
Ceppe, Agathe [2 ]
Conlon, Brian P. [1 ,2 ]
Muhlebach, Marianne S. [2 ,3 ]
机构
[1] Univ North Carolina Chapel Hill, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA
[2] Univ North Carolina Chapel Hill, Mars Lung Inst, Chapel Hill, NC 27599 USA
[3] Univ North Carolina Chapel Hill, Dept Pediat, Chapel Hill, NC 27599 USA
来源
MICROBIOLOGY SPECTRUM | 2023年 / 11卷 / 01期
关键词
antibiotic tolerance; MRSA; cystic fibrosis; persistence; treatment outcome; Staphylococcus aureus; ANTIMICROBIAL SUSCEPTIBILITY; PERSISTER CELLS; ABILITY;
D O I
10.1128/spectrum.04061-22
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Methicillin-resistant Staphylococcus aureus (MRSA) is highly prevalent in U.S. cystic fibrosis (CF) patients and is associated with worse clinical outcomes in CF. These infections often become chronic despite repeated antibiotic therapy. Here, we assessed whether bacterial phenotypes, including antibiotic tolerance, can predict the clinical outcomes of MRSA infections. MRSA isolates (n = 90) collected at the incident (i.e., acute) and early infection states from 57 patients were characterized for growth rates, biofilm formation, hemolysis, pigmentation, and vancomycin tolerance. The resistance profiles were consistent with those in prior studies. Isolates from the early stage of infection were found to produce biofilms, and 70% of the isolates exhibited delta-hemolysis, an indicator of agr activity. Strong vancomycin tolerance was present in 24% of the isolates but was not associated with intermediate vancomycin susceptibility. There were no associations between these phenotypic measures, antibiotic tolerance, and MRSA clearance. Our research suggests that additional factors may be relevant for predicting the clearance of MRSA.IMPORTANCE Chronic MRSA infections remain challenging to treat in patients with cystic fibrosis (CF). The ability of the bacterial population to survive high concentrations of bactericidal antibiotics, including vancomycin, despite lacking resistance is considered one of the main reasons for treatment failures. The connection between antibiotic tolerance and treatment outcomes remains unexplored and can be crucial for prognosis and regimen design toward eradication. In this study, we measured the capacity of 90 MRSA isolates from CF patients to form vancomycin-tolerant persister cells and evaluated their correlation with the clinical outcomes. Additionally, various traits that could reflect the metabolism and/or virulence of those MRSA isolates were systematically phenotyped and included for their predictive power. Our research highlights that despite the importance of antibiotic tolerance, additional factors need to be considered for predicting the clearance of MRSA. Chronic MRSA infections remain challenging to treat in patients with cystic fibrosis (CF). The ability of the bacterial population to survive high concentrations of bactericidal antibiotics, including vancomycin, despite lacking resistance is considered one of the main reasons for treatment failures.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Role of Berberine in the Treatment of Methicillin-Resistant Staphylococcus aureus Infections
    Ming Chu
    Ming-bo Zhang
    Yan-chen Liu
    Jia-rui Kang
    Zheng-yun Chu
    Kai-lin Yin
    Ling-yu Ding
    Ran Ding
    Rong-xin Xiao
    Yi-nan Yin
    Xiao-yan Liu
    Yue-dan Wang
    Scientific Reports, 6
  • [32] Role of Berberine in the Treatment of Methicillin-Resistant Staphylococcus aureus Infections
    Chu, Ming
    Zhang, Ming-bo
    Liu, Yan-chen
    Kang, Jia-rui
    Chu, Zheng-yun
    Yin, Kai-lin
    Ding, Ling-yu
    Ding, Ran
    Xiao, Rong-xin
    Yin, Yi-nan
    Liu, Xiao-yan
    Wang, Yue-dan
    SCIENTIFIC REPORTS, 2016, 6
  • [33] Guidelines for the treatment on infections caused by methicillin-resistant Staphylococcus aureus
    Mensa, J.
    Barberan, J.
    Llinares, P.
    Picazo, J. J.
    Bouza, E.
    Alvarez Lerma, F.
    Borges, M.
    Serrano, R.
    Leon, C.
    Guirao, X.
    Arias, J.
    Carreras, E.
    Sanz, M. A.
    Garcia Rodriguez, J. A.
    REVISTA ESPANOLA DE QUIMIOTERAPIA, 2008, 21 (04) : 234 - 258
  • [34] Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections
    Micek, Scott T.
    CLINICAL INFECTIOUS DISEASES, 2007, 45 : S184 - S190
  • [35] Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children
    Kaplan, SL
    Afghani, B
    Lopez, P
    Wu, EB
    Fleishaker, D
    Edge-Padbury, B
    Naberhuis-Stehouwer, S
    Bruss, JB
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2003, 22 (09) : S176 - S183
  • [36] TREATMENT OF INFECTIONS DUE TO METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS
    WATANAKUNAKORN, C
    ANNALS OF INTERNAL MEDICINE, 1982, 97 (03) : 376 - 378
  • [38] Update on prevalence and treatment of methicillin-resistant Staphylococcus aureus infections
    Loffler, Cindy A.
    MacDougo, Conan
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2007, 5 (06) : 961 - 981
  • [39] TREATMENT OF INFECTIONS DUE TO METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS
    WALDVOGEL, FA
    JOURNAL OF HOSPITAL INFECTION, 1986, 7 : 37 - 46
  • [40] Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children
    Frank, AL
    Marcinak, JF
    Mangat, PD
    Tjhio, JT
    Kelkar, S
    Schreckenberger, PC
    Quinn, JP
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2002, 21 (06) : 530 - 534